What changed for GLP-1 access: Thursday, August 13, 2026

On Thursday, August 13, 2026, Eli Lilly filed four separate lawsuits against companies involved in selling peptides or compounded GLP-1 products. All four target parts of the compounded and gray-market supply chain that many patients turn to when brand-name drugs are hard to find or too expensive. If Lilly prevails in these cases, some of the sources people currently use to get these medications could become harder to reach. The cases are early, but together they signal a broader push against this market.

The case against Legendary Peptides appears to target copycat or compounded versions of Lilly's drugs, though the public filing does not yet spell out the specific allegations. Compounded and copycat products have become a common way for patients to access GLP-1 medications when the brand-name versions are unavailable or unaffordable. Because details are limited at this stage, it is not yet clear how broad the claims are or which specific products are involved. Patients who rely on similar products from other sellers may want to watch how this case develops, since it could set an early tone for how Lilly approaches these lawsuits going forward.

Lone Star Peptide Co. sells peptides that fall into the same gray-market category many patients have used to get GLP-1 medications outside the traditional pharmacy system. These products often exist because demand for brand-name drugs has outpaced supply, and buyers have looked for other ways to get similar compounds. A ruling against the company could reduce the number of gray-market options available, which would affect people who have come to depend on them. The outcome here matters less for its details right now and more for what it signals about how aggressively Lilly plans to pursue sellers in this space.

Striker Pharmacy is a compounding pharmacy, which places it in a different position than a peptide seller, since compounding pharmacies are generally allowed to prepare medications under certain regulatory conditions. If Lilly wins this case, it could limit what compounding pharmacies are permitted to produce or sell when it comes to GLP-1 drugs. That would directly affect patients who use compounded versions prescribed through a pharmacy rather than purchased through less regulated channels. The result may take time to unfold, but it is worth tracking, since compounding pharmacies serve as a more regulated alternative to the broader gray market.

Texas Peptides Inc. supplies the raw ingredients used in compounded GLP-1 products, which places this case further upstream in the supply chain than the others. A win for Lilly here could shrink the pool of compounded ingredients available to pharmacies and manufacturers who rely on suppliers like this one. That kind of restriction would ripple outward, potentially affecting multiple compounding pharmacies rather than a single seller. Because ingredient supply sits at the foundation of the compounded drug market, this case may end up having a wider reach than the others, even though it targets just one supplier.

None of these four cases has reached a resolution yet, and the outcomes will likely take months to play out. Readers who currently use compounded or gray-market GLP-1 products may want to keep an eye on how these lawsuits proceed, since the results could affect what is available and from whom. It may also help to talk with a pharmacist or prescriber about how dependent your current access is on these kinds of sources, so you are not caught off guard if the market shifts. This is a legal and regulatory matter, not a medical one, so any decisions about your treatment should go through your own healthcare provider.

By Amanda Bonello